

SCHEDULING STATUS

S2

URISPAS 200, 200 mg film-coated tablets
Flavoxate hydrochloride
Contains sugar (lactose monohydrate): 64 mg

Read all of this leaflet carefully before you start taking URISPAS 200

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, pharmacist, nurse or other health care provider.
- URISPAS 200 has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

What is in this leaflet

1. What URISPAS 200 is and what it is used for
2. What you need to know before you take URISPAS 200
3. How to take URISPAS 200
4. Possible side effects
5. How to store URISPAS 200
6. Contents of the pack and other information

1. What URISPAS 200 is and what it is used for

URISPAS 200 contains flavoxate hydrochloride. It is a non-specific, direct-acting, smooth muscle relaxant. URISPAS 200 is therefore an anti-spasmodic which works by inhibiting contractions in the urinary tract, thereby reducing urinary symptoms and associated pain. URISPAS 200 is used for its antispasmodic (preventing or relieving spasms) action in urological disorders (disorders of or relating to urinary tract.)

2. What you need to know before you take URISPAS 200

Do not take URISPAS 200:

- if you are hypersensitive (allergic) to flavoxate hydrochloride or any of the other ingredients of URISPAS 200 listed in section 6.
- if you have a history of, suffer from or think you may have a blockage of the stomach, bowel, or urinary tract; or if you suffer from bleeding from the stomach or bowel.

PATIENT INFORMATION LEAFLET

- if you have an inability to swallow (achalasia).
- if you are or think that you might be pregnant or if you are breastfeeding.
- if you suffer from urinary retention (the inability to empty the bladder completely).
- if you have glaucoma (increased pressure of the fluid inside the eye).
- if you have a muscle disorder called myasthenia gravis (disorder causing weakness in the skeletal muscles).

URISPAS 200 is not recommended for use in children under 12 years of age.

Warnings and precautions

Take special care with URISPAS 200:

- if you have kidney problems.
- if you think you may have glaucoma (increased pressure of the fluid inside the eye).
- if you have serious, uncontrolled disorders that is causing a blockage of the lower urinary tract.
- if you feel drowsy, you should wait longer before taking your next dosage. See also “Driving and using machines”.

Children

Do not give your child URISPAS 200, as the safety and efficacy of URISPAS 200 in children (aged < 12 years) have not been established.

Other medicines and URISPAS 200

Always tell your health care provider if you are taking any other medicine. (This includes all complementary or traditional medicines.)

No interaction studies have been performed on URISPAS 200. Please consult your doctor, pharmacist or other health care provider for advice.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, please consult your doctor, pharmacist or other health care provider for advice before taking URISPAS 200. Do not take URISPAS 200 during pregnancy or breastfeeding.

Driving and using machines

It is not always possible to predict to what extent URISPAS 200 may interfere with the daily activities of a patient. Patients should ensure that they do not engage in the above activities until they are aware of the measure to which URISPAS 200 affects them.

URISPAS 200 may cause drowsiness, blurred vision and dizziness which can affect your ability to drive a vehicle and use machines.

URISPAS 200 contains lactose monohydrate

Patients with the rare hereditary conditions of lactose/fructose or galactose intolerance should not take URISPAS 200.

3. How to take URISPAS 200

Do not share medicines prescribed for you with any other person. Always take URISPAS 200 exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The usual dose is one tablet three times a day for as long as is required.

Do not break the tablet but swallow it whole, preferably with a glass of water.

If you have the impression that the effect of URISPAS 200 is too strong or too weak, tell your doctor or pharmacist.

If you take more URISPAS 200 than you should

The most likely symptoms of overdose are blurred vision, dry mouth, drowsiness and diarrhoea or constipation. Treatment by your doctor or healthcare professional is symptomatic and supportive.

In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison centre.

If you forget to take URISPAS 200

If you miss a dose, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not take a double dose to make up for forgotten individual doses.

4. Possible side effects

URISPAS 200 can have side effects.

Not all side effects reported for URISPAS 200 are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking URISPAS 200, please consult your health care provider for advice.

PATIENT INFORMATION LEAFLET

If any of the following happens, stop taking URISPAS 200 and tell your doctor immediately or go to the casualty department at your nearest hospital:

- swelling of the hands, feet, ankles, face, lips and mouth or throat, which may cause difficulty in swallowing or breathing,
- rash or itching,
- fainting.

These are all very serious side effects. If you have them, you may have had a serious reaction to URISPAS 200. You may need urgent medical attention or hospitalisation.

Tell your doctor immediately or go to the casualty department at your nearest hospital if you notice any of the following:

Less frequent side effects:

- palpitations (rapid irregular action of the heart).
- tachycardia (increased rate of heartbeat).

Side effects with an unknown frequency:

- yellowing of the skin and eyes (also called jaundice), liver disorders, abnormal liver enzyme levels.

These are all serious side effects. You may need urgent medical attention.

Tell your doctor as soon as possible if you notice any of the following:

Frequent

- Nausea

Less frequent:

- blood disorders (increased or decreased white blood cell count).
- drowsiness, dizziness, headache, confusion (especially if you are elderly), nervousness, sleepiness, sensation of whirling and loss of balance (vertigo).
- blurred vision, visual impairment, eye disorders (disturbances in eye accommodation), increased eye tension.
- diarrhoea, dry mouth, dyspepsia (heartburn, indigestion), dysphagia (difficulty swallowing) and vomiting.
- urticaria (allergic skin rash), itch (pruritus) and other dermatoses (diseases of the skin).
- dysuria (painful or difficult urination), inability to completely empty the bladder.
- fatigue (unusual weakness or tiredness), and fever.

Side effects with an unknown frequency:

- feeling confused.
- glaucoma (increased pressure of the fluid inside the eye).
- redness of the skin.

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

Reporting of side effects

If you get side effects, talk to your doctor, pharmacist or nurse. You can also report side effects to SAHPRA via the 6.04 Adverse Drug Reaction Reporting Form, found online under SAHPRA's publications: <https://www.sahpra.org.za/Publications/Index/8>. By reporting side effects, you can help provide more information on the safety of URISPAS 200.

5. How to store URISPAS 200

- Store all medicines out of reach of children.
- Store at or below 30 °C.
- Protect from moisture and light.
- Keep the blister strips in the outer carton until required for use.

Return all unused medicine to your pharmacist.

Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

6. Contents of the pack and other information

What URISPAS 200 contains

The active substance is 200 mg flavoxate hydrochloride.

The other ingredients are:

Tablet Core

Lactose monohydrate, magnesium stearate, microcrystalline cellulose (Avicel PH-102), povidone (Polyvinylpyrrolidone K30), sodium starch glycolate (Type A), talc.

Coating

Macrogol 6000, magnesium stearate, Sepifilm® (coating consisting of: hypromellose, macrogol stearate, microcrystalline cellulose), titanium dioxide (CI 77891).

What URISPAS 200 looks like and contents of the pack

White, homogeneous film-coated tablets with "F200" embossed.

PATIENT INFORMATION LEAFLET

Cartons of 15 tablets: Each carton contains 1 blister strip containing 15 tablets.

Cartons of 90 tablets: Each carton contains 6 blister strips containing 15 tablets per blister strip.

Not all pack sizes may be marketed.

Holder of Certificate of Registration

Adcock Ingram Limited

1 New Road,

Erand Gardens,

Midrand, 1685

0860 ADCOCK (232625)

This leaflet was last revised in

10 May 2022

Registration number

29/18/0428

Botswana: S2 B9300825

Namibia: NS1 04/18/0744